BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 37979019)

  • 1. The Evolving Treatment Landscape of Medullary Thyroid Cancer.
    Laganà M; Cremaschi V; Alberti A; Vodopivec Kuri DM; Cosentini D; Berruti A
    Curr Treat Options Oncol; 2023 Dec; 24(12):1815-1832. PubMed ID: 37979019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
    Jara MA
    Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
    Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
    Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
    Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
    Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
    [No Abstract]   [Full Text] [Related]  

  • 8. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
    Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
    Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
    Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Guidelines for Management of Medullary Thyroid Carcinoma.
    Kim M; Kim BH
    Endocrinol Metab (Seoul); 2021 Jun; 36(3):514-524. PubMed ID: 34154310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medullary Thyroid Cancer: Updates and Challenges.
    Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
    Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
    Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State of the art and future directions in the systemic treatment of medullary thyroid cancer.
    Jager EC; Broekman KE; Kruijff S; Links TP
    Curr Opin Oncol; 2022 Jan; 34(1):1-8. PubMed ID: 34669647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
    Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V
    Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
    Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
    Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
    Saltiki K; Simeakis G; Karapanou O; Alevizaki M
    Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET kinase inhibitors for
    Vodopivec DM; Hu MI
    Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.